Ganaxolone in Posttraumatic Stress Disorder (PTSD)
Public ClinicalTrials.gov record NCT01339689. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Proof-of-Concept, Double-blind, Randomized, Placebo-controlled Study of Ganaxolone in Posttraumatic Stress Disorder
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 2 proof-of-concept study is a double-blind, randomized, placebo-controlled, 15-week investigation of ganaxolone versus placebo for the treatment of Posttraumatic Stress Disorder (PTSD). Up to 120 participants will be enrolled and randomized to receive either ganaxolone or placebo for 6 weeks. After 6 weeks of randomized treatment all participants will continue for 6 weeks on ganaxolone. The aim of the study is to assess the efficacy of ganaxolone compared to placebo for the treatment of PTSD symptoms after 6 weeks of treatment using the Clinician-Administered PTSD Rating Scale (CAPS). The second aim of the study is to evaluate the safety and tolerability of ganaxolone in the PTSD population.
Study identification
- NCT ID
- NCT01339689
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 112 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2011
- Primary completion
- Dec 31, 2013
- Completion
- Feb 28, 2014
- Last update posted
- Dec 28, 2022
2011 – 2014
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| VA San Diego Healthcare System/ University of California, San Diego | San Diego | California | 92093 | — |
| Washington DC VA Medical Center/ Uniformed Services University of the Health Services | Washington D.C. | District of Columbia | 20422 | — |
| VA Boston Healthcare Services/ Spaulding Rehabilitation Hospital | Boston | Massachusetts | 02130 | — |
| Manchester VA Medical Center/ Dartmouth College | Manchester | New Hampshire | 03104 | — |
| Durham VA Medical Center /Duke University Medical Center | Durham | North Carolina | 27705 | — |
| Cincinnati VA Medical Center/ University of Cincinnati | Cincinnati | Ohio | 45220 | — |
| Charleston VA Medica Center/ Medical University of South Carolina | Charleston | South Carolina | 29401 | — |
| White River Junction VA Medical Center/ Dartmouth College | White River Junction | Vermont | 05009 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01339689, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 28, 2022 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01339689 live on ClinicalTrials.gov.